CN106748872A - 酰基类神经氨酸酶抑制剂及其医药用途 - Google Patents
酰基类神经氨酸酶抑制剂及其医药用途 Download PDFInfo
- Publication number
- CN106748872A CN106748872A CN201710022543.7A CN201710022543A CN106748872A CN 106748872 A CN106748872 A CN 106748872A CN 201710022543 A CN201710022543 A CN 201710022543A CN 106748872 A CN106748872 A CN 106748872A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutically acceptable
- acetylamino
- isomers
- derivative
- cyclohexene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002911 sialidase inhibitor Substances 0.000 title claims description 5
- 229940123424 Neuraminidase inhibitor Drugs 0.000 title description 3
- 125000002252 acyl group Chemical group 0.000 title description 2
- -1 Oseltamivir primary amine Chemical class 0.000 claims abstract description 25
- 150000003839 salts Chemical class 0.000 claims abstract description 16
- 241000712461 unidentified influenza virus Species 0.000 claims abstract description 6
- 238000002360 preparation method Methods 0.000 claims abstract description 3
- 206010022000 influenza Diseases 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- IOVLJLFEXFRWGR-RRFJBIMHSA-N C(C)(=O)N[C@H]1[C@@H](C=C(C[C@@H]1NC(C)=O)C(=O)O)OC(CC)CC Chemical compound C(C)(=O)N[C@H]1[C@@H](C=C(C[C@@H]1NC(C)=O)C(=O)O)OC(CC)CC IOVLJLFEXFRWGR-RRFJBIMHSA-N 0.000 claims description 7
- XRKZWZDSIULWIR-GZBFAFLISA-N C(C)(=O)N[C@H]1[C@@H](C=C(C[C@@H]1NC(CF)=O)C(=O)O)OC(CC)CC Chemical compound C(C)(=O)N[C@H]1[C@@H](C=C(C[C@@H]1NC(CF)=O)C(=O)O)OC(CC)CC XRKZWZDSIULWIR-GZBFAFLISA-N 0.000 claims description 7
- WUEJPOIXUWTXKV-YNEHKIRRSA-N C(C)(=O)N[C@H]1[C@@H](C=C(C[C@@H]1NC(C(F)(F)F)=O)C(=O)O)OC(CC)CC Chemical compound C(C)(=O)N[C@H]1[C@@H](C=C(C[C@@H]1NC(C(F)(F)F)=O)C(=O)O)OC(CC)CC WUEJPOIXUWTXKV-YNEHKIRRSA-N 0.000 claims description 6
- BGFKCPOFMGHRPE-YNEHKIRRSA-N C(C)(=O)N[C@H]1[C@@H](C=C(C[C@@H]1NC(C(F)F)=O)C(=O)O)OC(CC)CC Chemical compound C(C)(=O)N[C@H]1[C@@H](C=C(C[C@@H]1NC(C(F)F)=O)C(=O)O)OC(CC)CC BGFKCPOFMGHRPE-YNEHKIRRSA-N 0.000 claims description 6
- NLPASAZGMPNSRT-YQVWRLOYSA-N CCCCCC(=O)N[C@H]1CC(=C[C@H]([C@@H]1NC(=O)C)OC(CC)CC)C(=O)O Chemical compound CCCCCC(=O)N[C@H]1CC(=C[C@H]([C@@H]1NC(=O)C)OC(CC)CC)C(=O)O NLPASAZGMPNSRT-YQVWRLOYSA-N 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 2
- 229940042406 direct acting antivirals neuraminidase inhibitors Drugs 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 2
- 150000001335 aliphatic alkanes Chemical class 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 229930192474 thiophene Natural products 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 229960003752 oseltamivir Drugs 0.000 abstract description 9
- 208000035473 Communicable disease Diseases 0.000 abstract description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 9
- 102000005348 Neuraminidase Human genes 0.000 description 8
- 108010006232 Neuraminidase Proteins 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 229960002194 oseltamivir phosphate Drugs 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 3
- NENPYTRHICXVCS-YNEHKIRRSA-N oseltamivir acid Chemical compound CCC(CC)O[C@@H]1C=C(C(O)=O)C[C@H](N)[C@H]1NC(C)=O NENPYTRHICXVCS-YNEHKIRRSA-N 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108060003393 Granulin Proteins 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- QEWYKACRFQMRMB-UHFFFAOYSA-N fluoroacetic acid Chemical compound OC(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 208000037797 influenza A Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- PSGQCCSGKGJLRL-UHFFFAOYSA-N 4-methyl-2h-chromen-2-one Chemical group C1=CC=CC2=C1OC(=O)C=C2C PSGQCCSGKGJLRL-UHFFFAOYSA-N 0.000 description 1
- 201000001178 Bacterial Pneumonia Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 206010035737 Pneumonia viral Diseases 0.000 description 1
- 101710165315 Sialidase A Proteins 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 229940124393 anti-influenza virus drug Drugs 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- PBWZKZYHONABLN-UHFFFAOYSA-N difluoroacetic acid Chemical compound OC(=O)C(F)F PBWZKZYHONABLN-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 150000003141 primary amines Chemical group 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 208000009421 viral pneumonia Diseases 0.000 description 1
- 229960001028 zanamivir Drugs 0.000 description 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/52—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明涉及药物化学领域,具体是一类奥司他韦伯胺酰化的衍生物、其制备方法及其医药用途,医药用途主要用于治疗由流感病毒引起的一系列感染性疾病。具体地,本发明提供通式(I)所示的衍生物及其药学上可接受的盐,异构体,其中,R1、R2如权利要求书和说明书所述。
Description
技术领域
本发明涉及药物化学领域,具体是一类奥司他韦伯胺酰化的衍生物、其制备方法及其医药用途,医药用途主要用于治疗由流感病毒引起的一系列感染性疾病。
背景技术
流行性感冒(简称流感)是由流感病毒引起的急性呼吸道感染病,还能引起流感病毒性肺炎和继发细菌性肺炎。老年人以及患有各种慢性病或者体质虚弱者患流感后容易出现严重并发症,死亡率较高,容易造成大流行。历史上出现过三次流感大爆发,给人类一次又一次的沉重打击,分别是1918年西班牙流感,1957年亚洲流感和1968年香港流感。时至今日,流感仍然是威胁人类健康的一个疾病。
目前,用于抗流感病毒药物主要有两种,基质蛋白M2抑制剂和神经氨酸酶抑制剂,基质蛋白M2抑制剂主要是金刚烷胺类药物,这类药物能穿透血脑屏障,故具有中枢神经系统毒副反应,并且很容易产生耐药性。
神经氨酸酶抑制剂是目前为止最为有效的一类药物,代表药物有扎那米韦和磷酸奥司他韦。这一类药物只有磷酸奥司他韦可以用于口服,奥司他韦在体内肝脏经酯酶代谢为活性成分,后者可以高度选择性地与A型或B型流感病毒的神经氨酸酶结合,阻断流感病毒神经氨酸酶对流感感染细胞表面的唾液酸残基的裂解,从而抑制新生病毒颗粒从宿主细胞释放,因此奥司他韦对A型(包括H5N1)和B型的不同亚型流感病毒均有效。随着临床上的不断使用,有些流感病毒出现了耐药性。
发明内容
本发明中包含的衍生物是对奥司他韦的伯胺基团修饰改造而得的。药理活性测试结果表明,对神经氨酸酶A/Anhui/1/2005(H5N1)有酶抑制活性,部分化合物表现了较强的抑制作用,有进一步开发的价值。
本发明提供具有通式(I)所示的衍生物及其药学上可接受的盐,异构体:
其中:
R1、R2独立的表示氢原子、取代或未取代的C1-C6烷基,所述取代基为卤素,5-10元芳香环。
本发明优选通式(I)所示的衍生物及其药学上可接受的盐,异构体:
其中,R1、R2独立的表示氢原子、取代或未取代的C1-C4烷基,所述取代基为卤素,5-6元芳香环。
本发明优选通式(I)所示的衍生物及其药学上可接受的盐,异构体:
其中,R1、R2独立的表示氢原子、取代或未取代的C1-C4烷基,所述取代基为F、Cl、苯环。
本发明优选通式(I)所示的衍生物及其药学上可接受的盐,异构体:
其中,R1为氢原子、甲基、三氟甲基、二氟甲基、一氟甲基;R2为氢原子。
本发明优选如下化合物及其药学上可接受的盐,异构体:
(3R,4R,5S)-4-乙酰氨基-5-乙酰氨基-3-(1-乙基丙氧基)-1-环己烯-1-羧酸(Ⅰ-1)
(3R,4R,5S)-4-乙酰氨基-5-三氟乙酰氨基-3-(1-乙基丙氧基)-1-环己烯-1-羧酸(Ⅰ-2)
(3R,4R,5S)-4-乙酰氨基-5-二氟乙酰氨基-3-(1-乙基丙氧基)-1-环己烯-1-羧酸(Ⅰ-3)
(3R,4R,5S)-4-乙酰氨基-5-一氟乙酰氨基-3-(1-乙基丙氧基)-1-环己烯-1-羧酸(Ⅰ-4)
(3R,4R,5S)-4-乙酰氨基-5-正己酰氨基-3-(1-乙基丙氧基)-1-环己烯-1-羧酸(Ⅰ-5)
(3R,4R,5S)-4-乙酰氨基-5-(4-苯丁基酰氨基)-3-(1-乙基丙氧基)-1-环己烯-1-羧酸(Ⅰ-6)
本发明中的化合物制备如下:
本发明中的化合物进行了神经氨酸酶的抑制活性测试。测试原理为MUNANA(2’-(4-methylumbelliferyl)-α-N-acetylneuraminic acid)是神经氨酸酶的特异性底物,经神经氨酸酶代谢所生成的物质,在355nm的光照激发下,能够产生460nm的荧光,当测试的化合物与神经氨酸酶作用时,导致该特异性底物的结合率发生变化,从而产生荧光强度的变化,通过荧光强度变化反映神经氨酸酶的活性,从而计算出化合物对神经氨酸酶的抑制率,进一步得到相应的IC50值。
试验方法:
96孔板中每孔加入10μL含有酶的溶液,70μL缓冲液(33mM吗啉乙磺酸,4mMCaCl2),10μL的待测液,37°条件下孵育十分钟,然后加入100μM的荧光底物MUNANA 10μL,在37°条件下孵育30分钟,加150μL终止液(14mM NaOH的83%乙醇溶液)测定荧光强度,其中激发波长355nm,发射波长460nm。
实验结果为:
化合物名称 | I-1 | I-2 | I-3 | I-4 | I-5 | I-6 |
IC50/μM | 0.238 | 0.266 | 0.19 | 0.228 | >20 | >20 |
实验结果表明Ⅰ-1、Ⅰ-2、Ⅰ-3、Ⅰ-4表现了较强的神经氨酸酶抑制活性,与文献中报道的达菲的活性成分——奥司他韦羧酸相当。本发明的化合物不再是两性离子,只具有酸性,去除了碱性结构片段。因此,本发明中的化合物有开发成药物的潜质。
具体实施方式
实施实例1
(3R,4R,5S)-4-乙酰氨基-5-乙酰氨基-3-(1-乙基丙氧基)-1-环己烯-1-羧酸乙酯(Ⅱ-1)
往50mL圆底烧瓶中加入130mg(0.417mmol)奥司他韦,238mg HATU(0.625mmol),182μL DIPEA(1.04mmol),30mg冰乙酸(0.50mmol),室温搅拌反应,反应结束后,有机相依次用1N HCl溶液、饱和碳酸钠溶液、饱和氯化钠溶液洗涤,无水硫酸钠干燥,浓缩,经柱层析纯化得固体110mg,收率为74.5%。
实施实例2
(3R,4R,5S)-4-乙酰氨基-5-乙酰氨基-3-(1-乙基丙氧基)-1-环己烯-1-羧酸(Ⅰ-1)
取上一步产物(3R,4R,5S)-4-乙酰氨基-5-乙酰氨基-3-(1-乙基丙氧基)-1-环己烯-1-羧酸乙酯(Ⅱ-1)
110mg(0.31mmol),加入甲醇10mL和0.78mL 1N氢氧化钠水溶液,补加1.22mL去离子水,使V(甲醇):V(水)=5:1,室温搅拌反应,反应结束后,减压蒸除甲醇,调节pH至1-2,析出沉淀,过滤,干燥得白色固体80mg,收率为82.6%。1H NMR(400MHz,DMSO)δ12.56(s,1H),7.77(d,J=9.2Hz,1H),7.66(d,J=8.9Hz,1H),6.60(s,0H),4.07(d,J=8.3Hz,1H),3.88(m,1H),3.78–3.66(m,1H),3.42–3.35(m,1H),2.49–2.41(m,1H),2.19-2.11(m,0H),1.77(s,3H),1.76(s,3H),1.47-1.33(m,4H),0.83(t,J=7.4Hz,3H),0.76(t,J=7.4Hz,3H);MS(ESI):349.2[M+Na]+,325.0[M-H]-。
实施实例3
(3R,4R,5S)-4-乙酰氨基-5-三氟乙酰氨基-3-(1-乙基丙氧基)-1-环己烯-1-羧酸乙酯(Ⅱ-2)
实施操作同实施实例1,以奥司他韦和三氟乙酸为反应原料。得白色固体43mg,收率为18%。
实施实例4
(3R,4R,5S)-4-乙酰氨基-5-三氟乙酰氨基-3-(1-乙基丙氧基)-1-环己烯-1-羧酸(Ⅰ-2)
实施操作同实施实例2,以(3R,4R,5S)-4-乙酰氨基-5-三氟乙酰氨基-3-(1-乙基丙氧基)-1-环己烯-1-羧酸乙酯(Ⅱ-2)为反应原料,得白色固体26mg,收率为65%。1H NMR(400MHz,MeOD)δ6.82(s,1H),4.24–4.10(m,2H),3.99(dd,J=11.3,8.8Hz,1H),3.42(p,J=5.6Hz,1H),2.69(dd,J=17.5,5.4Hz,1H),2.49–2.38(m,1H),1.60–1.40(m,4H),0.93(t,J=7.4Hz,3H),0.88(t,J=7.4Hz,3H)。MS(ESI):379.0[M-H]-。
实施实例5
(3R,4R,5S)-4-乙酰氨基-5-二氟乙酰氨基-3-(1-乙基丙氧基)-1-环己烯-1-羧酸乙酯(Ⅱ-3)
实施操作同实施实例1,奥司他韦和二氟乙酸为反应原料,经处理得到白色固体226mg,收率为84%。
实施实例6
(3R,4R,5S)-4-乙酰氨基-5-二氟乙酰氨基-3-(1-乙基丙氧基)-1-环己烯-1-羧酸(Ⅰ-3)
实施操作同实施实例2,以226mg(3R,4R,5S)-4-乙酰氨基-5-二氟乙酰氨基-3-(1-乙基丙氧基)-1-环己烯-1-羧酸乙酯(Ⅱ-3),经处理得到白色固体174mg,收率为83%。1HNMR(400MHz,DMSO)δ12.63(s,1H),8.67(d,J=8.8Hz,1H),7.88(d,J=9.1Hz,1H),6.63(s,1H),6.16(t,J=53.7Hz,1H),4.11(d,J=8.1Hz,1H),4.02–3.88(m,1H),3.88–3.73(m,1H),3.40–3.36(p,J=5.6Hz,1H),2.47(d,J=5.2Hz,1H),2.40-2.29(m,1H),1.76(s,3H),1.50-1.32(m,4H),0.84(t,J=7.4Hz,3H),0.77(t,J=7.4Hz,3H)。MS(ESI):361.0[M-H]-。
实施实例7
(3R,4R,5S)-4-乙酰氨基-5-一氟乙酰氨基-3-(1-乙基丙氧基)-1-环己烯-1-羧酸乙酯(Ⅱ-4)
实施操作同实施实例1,以奥司他韦和一氟乙酸为反应原料,经处理得到白色固体230mg,收率为84%。
实施实例8
(3R,4R,5S)-4-乙酰氨基-5-一氟乙酰氨基-3-(1-乙基丙氧基)-1-环己烯-1-羧酸(Ⅰ-4)
实施操作同实施实例2,以230mg((3R,4R,5S)-4-乙酰氨基-5-一氟乙酰氨基-3-(1-乙基丙氧基)-1-环己烯-1-羧酸乙酯(Ⅱ-4)为反应原料,经处理得到白色固体177mg,收率为83.2%。MS(ESI):343.0[M-H]-。
实施实例9
(3R,4R,5S)-4-乙酰氨基-5-正己酰氨基-3-(1-乙基丙氧基)-1-环己烯-1-羧酸乙酯(Ⅱ-5)
实施操作同实施实例1,以奥司他韦和正己酸为反应原料,经处理得到白色固体220mg,收率为82%。
实施实例10
(3R,4R,5S)-4-乙酰氨基-5-正己酰氨基-3-(1-乙基丙氧基)-1-环己烯-1-羧酸(Ⅰ-5)
实施操作同实施实例2,以220mg(3R,4R,5S)-4-乙酰氨基-5-正己酰氨基-3-(1-乙基丙氧基)-1-环己烯-1-羧酸乙酯(Ⅱ-5)为反应原料,经处理得到白色固体183mg,收率为89.3%。
1H NMR(400MHz,DMSO)δ12.56(s,1H),7.81(d,J=9.2Hz,1H),7.63(d,J=9.0Hz,1H),6.60(s,1H),4.06(d,J=8.5Hz,1H),3.95–3.82(m,1H),3.78-3.68(m,1H),3.41-3.36(m,1H),2.44(dd,J=17.6,5.1Hz,1H),2.22–2.09(m,1H),2.00(t,J=7.0Hz,2H),1.76(s,3H),1.50-1.33(m,6H),1.30–1.16(m,4H),0.88-0.81(m,6H),0.76(t,J=7.4Hz,3H).
MS(ESI):383.5[M+H]+,405.3[M+Na]+,421.4[M+K]+,381.1[M-H]-。
实施实例11
(3R,4R,5S)-4-乙酰氨基-5-(4-苯丁基酰胺基)-3-(1-乙基丙氧基)-1-环己烯-1-羧酸乙酯(Ⅱ-6)
实施操作同实施实例1,以奥司他韦和4-苯基丁酸为反应原料,经处理得到白色固体165mg,收率为76%。
实施实例12
(3R,4R,5S)-4-乙酰氨基-5-(4-苯丁基酰胺基)-3-(1-乙基丙氧基)-1-环己烯-1-羧酸(Ⅰ-6)
实施操作同实施实例2,以230mg((3R,4R,5S)-4-乙酰氨基-5-一氟乙酰氨基-3-(1-乙基丙氧基)-1-环己烯-1-羧酸乙酯(Ⅱ-4)为反应原料,经处理得到白色固体121mg,收率为78.1%。
1H NMR(400MHz,DMSO)δ12.59(s,1H),7.83(d,J=9.2Hz,1H),7.69(d,J=9.0Hz,1H),7.28(dd,J=9.6,5.2Hz,2H),7.22–7.14(m,3H),6.60(s,1H),4.06(d,J=8.3Hz,1H),3.98–3.85(m,1H),3.77-3.69(m,1H),3.40–3.36(m,1H),2.57–2.52(m,2H),2.44(dd,J=17.5,5.1Hz,1H),2.23–2.11(m,1H),2.07-(m,2H),1.81–1.74(m,2H),1.72(s,1H),1.49–1.31(m,2H),0.83(t,J=7.4Hz,3H),0.75(t,J=7.4Hz,3H).
MS(ESI):453.4[M+Na]+,469.3[M+K]+,429.2[M-H]-。
Claims (10)
1.通式(Ⅰ)所示的衍生物及其药学上可接受的盐,异构体:
其中,
R1、R2独立的表示氢原子、取代或未取代的C1-C6烷基,所述取代基为卤素、5-10元芳香环。
2.如权利要求1所述的衍生物及其药学上可接受的盐,异构体:其中,
所述R1为氢原子、取代或未取代的C1-C4烷烃,所述取代基为卤素、5-6元芳香环。
3.如权利要求1或2所述的衍生物及其药学上可接受的盐,异构体:其中,
R1为氢原子、取代或未取代的C1-C4烷烃,所述取代基为F、Cl、苯环、吡啶、吡喃、吡咯、噻吩、呋喃。
4.如权利要求1-3任何一项所述的衍生物及其药学上可接受的盐,异构体:其中,R1为氢原子、甲基、三氟甲基、二氟甲基、一氟甲基;R2为氢原子。
5.如下的衍生物及其药学上可接受的盐,异构体:
(3R,4R,5S)-4-乙酰氨基-5-乙酰氨基-3-(1-乙基丙氧基)-1-环己烯-1-羧酸(Ⅰ-1)
(3R,4R,5S)-4-乙酰氨基-5-三氟乙酰氨基-3-(1-乙基丙氧基)-1-环己烯-1-羧酸(Ⅰ-2)
(3R,4R,5S)-4-乙酰氨基-5-二氟乙酰氨基-3-(1-乙基丙氧基)-1-环己烯-1-羧酸(Ⅰ-3)
(3R,4R,5S)-4-乙酰氨基-5-一氟乙酰氨基-3-(1-乙基丙氧基)-1-环己烯-1-羧酸(Ⅰ-4)
(3R,4R,5S)-4-乙酰氨基-5-正己酰氨基-3-(1-乙基丙氧基)-1-环己烯-1-羧酸(Ⅰ-5)
(3R,4R,5S)-4-乙酰氨基-5-(4-苯丁基酰氨基)-3-(1-乙基丙氧基)-1-环己烯-1-羧酸(Ⅰ-6)。
6.权利要求1-5任何一项所述的衍生物及其药学上可接受的盐,异构体,其特征在于,还包括所述化合物的溶剂化物、多晶型体、对映体或外消旋混合物。
7.一种药用组合物,包含权利要求1-5中任何一项的衍生物及其药学上可接受的盐作为活性成分以及药学上可接受的赋型剂。
8.权利要求1-6任何一项所述的衍生物及其药学上可接受的盐,异构体或权利要求7所述的药物组合物在制备神经氨酸酶抑制剂中的应用。
9.权利要求1-6任何一项所述的衍生物及其药学上可接受的盐,异构体或权利要求7所述的药物组合物在制备治疗流感病毒感染引起的疾病的药物中的应用。
10.权利要求1-6任何一项所述的衍生物及其药学上可接受的盐,异构体或权利要求7所述的药物组合物在制备治疗流感的药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710022543.7A CN106748872A (zh) | 2017-01-12 | 2017-01-12 | 酰基类神经氨酸酶抑制剂及其医药用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710022543.7A CN106748872A (zh) | 2017-01-12 | 2017-01-12 | 酰基类神经氨酸酶抑制剂及其医药用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106748872A true CN106748872A (zh) | 2017-05-31 |
Family
ID=58947962
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710022543.7A Pending CN106748872A (zh) | 2017-01-12 | 2017-01-12 | 酰基类神经氨酸酶抑制剂及其医药用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106748872A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111470999A (zh) * | 2020-05-18 | 2020-07-31 | 中山万汉制药有限公司 | N-环己烯基-脂肪酰胺类化合物及其制备方法、组合物与用途 |
CN113214219A (zh) * | 2021-05-06 | 2021-08-06 | 山东大学 | 一种奥司他韦氨基衍生物及其制备方法与应用 |
-
2017
- 2017-01-12 CN CN201710022543.7A patent/CN106748872A/zh active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111470999A (zh) * | 2020-05-18 | 2020-07-31 | 中山万汉制药有限公司 | N-环己烯基-脂肪酰胺类化合物及其制备方法、组合物与用途 |
CN113214219A (zh) * | 2021-05-06 | 2021-08-06 | 山东大学 | 一种奥司他韦氨基衍生物及其制备方法与应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6903658B2 (ja) | インフルエンザウィルス感染に使用するための複素環インドール | |
CA2954751C (en) | Indoles for use in influenza virus infection | |
JP7001601B2 (ja) | インフルエンザウイルス感染に使用するための官能化ペンタン酸 | |
JP6989509B2 (ja) | インフルエンザウイルス感染における使用のためのアリール置換ピリミジン | |
JP5276583B2 (ja) | 抗真菌療法におけるクマリン誘導体の使用 | |
TW201004622A (en) | Aporphine compounds and pharmaceutical use thereof | |
KR20200069380A (ko) | 글루타르이미드 유도체, 이의 용도, 이를 기반으로 한 약학 조성물 및 글루타르이미드 유도체를 생산하는 방법 | |
EP2943469A1 (en) | Pyridone derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
EP2945945B1 (en) | Naphthyridinone derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
CN106748872A (zh) | 酰基类神经氨酸酶抑制剂及其医药用途 | |
JP5345073B2 (ja) | 抗ウイルス化合物 | |
WO2017046362A1 (en) | Pyrazolopyrazines and their use in the treatment, amelioration or prevention of a viral disease | |
CN109553554B (zh) | 含脲基的神经氨酸酶抑制剂及其医药用途 | |
CN108101804B (zh) | 羧基修饰的奥司他韦衍生物及其医药用途 | |
CN112724156B (zh) | 一种多环吡啶酮衍生物和药物组合物及其应用 | |
CA3106556A1 (en) | Pyrrolo[2,3-b]pyridin derivatives as inhibitors of influenza virus replication | |
RU2826250C1 (ru) | 6,8-Дифтор-2-(4-(трифторметил)фенил)хроман-4-он в качестве ингибитора репродукции вирусов гриппа А и В и способ его получения | |
CN112409218A (zh) | 含酰肼结构片段的神经氨酸酶抑制剂及其医药用途 | |
CN110015979A (zh) | 含磺酰胺基的神经氨酸酶抑制剂及其医药用途 | |
CN113214219A (zh) | 一种奥司他韦氨基衍生物及其制备方法与应用 | |
LI et al. | Rational Drug Design of Neuraminidase Inhibitors as Novel Anti-Influenza Agents | |
KR20130107554A (ko) | 신규한 n-페닐피리미딘-4-아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 인플루엔자 바이러스에 의해 유발되는 질환의 예방 또는 치료용 약학적 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |